BACKGROUND: Aim of this study was to investigate the long-term endocrine effects of treatment of childhood non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: A single-center cohort of 84 survivors (22 females) was included in this retrospective study. Median age was 21 years (9-40 years) and time after cessation of therapy 12 years (4-30 years). Height, weight, percentage fat, lean body mass (LBM), bone mineral content (BMC), bone mineral density of total body (BMD(TB)) and bone mineral density of lumbar spine (BMD(LS)) were measured. Thyroid-stimulating hormone (TSH), free thyroxin (fT4), insulin-like growth factor-1 (IGF-1), inhibin B and anti-müllerian hormone (AMH) levels were measured. Results were compared with Dutch controls. RESULTS: Height was lower in survivors [mean standard deviation score (SDS) -0.36, P = 0.002], but further analysis showed that shorter stature was already present at diagnosis (mean SDS -0.28, P = 0.023). Body mass index, percentage fat, BMC, BMD(TB) and BMD(LS) were not different from controls. LBM was lower in survivors (mean SDS -0.47, P = 0.008). TSH, fT4 and IGF-1 were normal in all survivors. Three of 20 adult females had low AMH levels and 23 of 42 adult males had low inhibin B levels. CONCLUSIONS: Twelve years after cessation of treatment, NHL survivors did not develop adiposity, osteoporosis or thyroid disease. Male survivors may be at risk for infertility.
BACKGROUND: Aim of this study was to investigate the long-term endocrine effects of treatment of childhood non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: A single-center cohort of 84 survivors (22 females) was included in this retrospective study. Median age was 21 years (9-40 years) and time after cessation of therapy 12 years (4-30 years). Height, weight, percentage fat, lean body mass (LBM), bone mineral content (BMC), bone mineral density of total body (BMD(TB)) and bone mineral density of lumbar spine (BMD(LS)) were measured. Thyroid-stimulating hormone (TSH), free thyroxin (fT4), insulin-like growth factor-1 (IGF-1), inhibin B and anti-müllerian hormone (AMH) levels were measured. Results were compared with Dutch controls. RESULTS: Height was lower in survivors [mean standard deviation score (SDS) -0.36, P = 0.002], but further analysis showed that shorter stature was already present at diagnosis (mean SDS -0.28, P = 0.023). Body mass index, percentage fat, BMC, BMD(TB) and BMD(LS) were not different from controls. LBM was lower in survivors (mean SDS -0.47, P = 0.008). TSH, fT4 and IGF-1 were normal in all survivors. Three of 20 adult females had low AMH levels and 23 of 42 adult males had low inhibin B levels. CONCLUSIONS: Twelve years after cessation of treatment, NHL survivors did not develop adiposity, osteoporosis or thyroid disease. Male survivors may be at risk for infertility.
Authors: Robyn E Karlage; Carmen L Wilson; Nan Zhang; Sue Kaste; Daniel M Green; Gregory T Armstrong; Leslie L Robison; Wassim Chemaitilly; Deo Kumar Srivastava; Melissa M Hudson; Kirsten K Ness Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: B Serio; L Pezzullo; R Fontana; S Annunziata; R Rosamilio; M Sessa; V Giudice; I Ferrara; M Rocco; G De Rosa; P Ricci; L Tauchmanovà; N Montuori; C Selleri Journal: Transl Med UniSa Date: 2013-01-04
Authors: Aurora Perez-Cornago; Paul N Appleby; Sarah Tipper; Timothy J Key; Naomi E Allen; Alexandra Nieters; Roel Vermeulen; Sandrine Roulland; Delphine Casabonne; Rudolf Kaaks; Renee T Fortner; Heiner Boeing; Antonia Trichopoulou; Carlo La Vecchia; Eleni Klinaki; Louise Hansen; Anne Tjønneland; Fabrice Bonnet; Guy Fagherazzi; Marie-Christine Boutron-Ruault; Valeria Pala; Giovanna Masala; Carlotta Sacerdote; Petra H Peeters; H B As Bueno-de-Mesquita; Elisabete Weiderpass; Miren Dorronsoro; J Ramón Quirós; Aurelio Barricarte; Diana Gavrila; Antonio Agudo; Signe Borgquist; Ann H Rosendahl; Beatrice Melin; Nick Wareham; Kay-Tee Khaw; Marc Gunter; Elio Riboli; Paolo Vineis; Ruth C Travis Journal: Int J Cancer Date: 2016-12-27 Impact factor: 7.396
Authors: Marjolein van Waas; Sebastian J C M M Neggers; Hein Raat; Caroline M van Rij; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: PLoS One Date: 2012-12-14 Impact factor: 3.240
Authors: Anne-Lotte L F van der Kooi; Eva Clemens; Linda Broer; Oliver Zolk; Julianne Byrne; Helen Campbell; Marleen van den Berg; Claire Berger; Gabriele Calaminus; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Riccardo Haupt; Melanie Kaiser; Tomas Kepak; Leontien Kremer; Jarmila Kruseova; Dalit Modan-Moses; Andreas Ranft; Claudia Spix; Peter Kaatsch; Joop S E Laven; Eline van Dulmen-den Broeder; André G Uitterlinden; Marry M van den Heuvel-Eibrink Journal: BMC Cancer Date: 2018-09-26 Impact factor: 4.430